Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-κB signaling

International Journal of Oncology

Volumn 29, Issue 3, 2006, Pages 695-703

  Jiang, Jiahua ^a   Slivova, Veronika ^a   Sliva, Daniel ^a,b,c  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; c myc; Estrogen receptor; NF B; Proliferation

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BREAST TUMOR; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GANODERMA LUCIDUM; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSACTIVATION;

BREAST NEOPLASMS; CELL PROLIFERATION; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; NF-KAPPA B; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-MYC; REISHI; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749356826     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.3.695     Document Type: Article

References (40)

1. Foster JS, Henley DC, Ahamed S and Wimalasena J: Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 12: 320-327, 2001.
2. Segars JH and Driggers PH: Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol Metab 13: 349-354, 2002.
3. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA and Sutherland RL: Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10: 179-186, 2003.
4. Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yoshida N and Yamaguchi Y: The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 10: 193-202, 2003.
5. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G and Genazzani AR: Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 69: 537-542, 2004.
6. Osborne CK and Schiff R: Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23: 1616-1622, 2005.
7. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ and Scanlan TS: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510, 1997.
8. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH Jr, Pestell RG and Kushner PJ: Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277: 24353-24360, 2002.
9. Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M and Gustafsson JA: Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci USA 97: 5936-5941, 2000.
10. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y and Hilakivi-Clarke LA: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339, 2003. (Pubitemid 37492898)
11. Pasqualini JR: The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 1654: 123-143, 2004.
12. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E and Pardee AB: The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 98: 10386-10391, 2001. (Pubitemid 32803029)
13. Liao DJ and Dickson RB: c-Myc in breast cancer. Endocr Relat Cancer 7: 143-164, 2000.
14. Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau AW, Hafer LJ, Yaswen P, Stampfer M, Rogers AE, Russo J and Sonenshein GE: Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21: 871-879, 2000. (Pubitemid 30265128)
15. Dubik D and Shiu RP: Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7: 1587-1594, 1992.
16. Schuchard M, Landers JP, Sandhu NP and Spelsberg TC: Steroid hormone regulation of nuclear proto-oncogenes. Endocr Rev 14: 659-669, 1993. (Pubitemid 24016655)
17. La Rosa FA, Pierce JW and Sonenshein GE: Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol 14: 1039-1044, 1994.
18. Sliva D, Rizzo MT and English D: Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 277: 3150-3157, 2002. (Pubitemid 34953176)
19. Gao JJ, Min BS, Ahn EM, Nakamura N, Lee H K and Hattori M: New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells. Chem Pharm Bul 50: 837-840, 2002.
20. Gao Y and Zhou S: Cancer prevention and treatment by Ganoderma, a mushroom with medicinal properties. Food Rev Int 19: 275-325, 2003. (Pubitemid 37044170)
21. Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr and Ho NW: Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun 298: 603-612, 2002.
22. Jiang J, SlivovaV, Harvey K, Valachovicova T and Sliva D: Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer 49: 209-216, 2004.
23. Jiang J, Sugimoto Y, Liu S, Chang HL, Park KY, Kulp SK and Lin YC: The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. Anticancer Res 24: 91-100, 2004. (Pubitemid 38279693)
24. Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, Ip C, Onate SA and Gao AC: Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 65: 3487-3492, 2005. (Pubitemid 40524636)
25. Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I and Chambon P: The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 8: 1981-1986, 1989.
26. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y and Muramatsu M: The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 243: 122-126, 1998. (Pubitemid 28414201)
27. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B and Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263, 1998. (Pubitemid 28513713)
28. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639, 1997. (Pubitemid 27281838)
29. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE: Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960, 1997. (Pubitemid 28022831)
30. Slivova V, Valachovicova T, Jiang J and Sliva D: Ganoderma lucidum inhibits invasiveness of breast cancer cells. J Cancer Integ Med 2: 25-30, 2004.
31. Sun JM, Chen HY and Davie JR: Effect of estradiol on histone acetylation dynamics in human breast cancer cells. J Biol Chem 276: 49435-49442, 2001. (Pubitemid 37370657)
32. Hsieh TC and Wu JM: Mechanism of action of herbal supplement PC-SPES: elucidation of effects of individual herbs of PC-SPES on proliferation and prostate specific gene expression in androgen-dependent LNCaP cells. Int J Oncol 20: 583-588, 2002.
33. Ikeda K, Arao Y, Otsuka H, Nomoto S, Horiguchi H, Kato S and Kayama F: Terpenoids found in the umbelliferae family act as agonists/antagonists for ER(alpha) and ERbeta: differential transcription activity between ferutinine-liganded ER(alpha) and ERbeta. Biochem Biophys Res Commun 291: 354-360, 2002. (Pubitemid 34694412)
34. Chen J and Thompson LU: Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Res Treat 80: 163-170, 2003. (Pubitemid 36886504)
35. Taylor IW, Hodson PJ, Green MD and Sutherland RL: Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res 43: 4007-4010, 1983. (Pubitemid 13041019)
36. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M and Gustafsson JA: Mechanisms of estrogen action. Physiol Rev 81: 1535-1565, 2001.
37. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y and Gayno RB: Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18: 71-82, 2005. (Pubitemid 40444649)
38. Wong MS and Murphy LC: Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells. J Steroid Biochem Mol Biol 39: 39-44, 1991.
39. Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, Pujol H and Rochefort H: Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene 6: 431-437, 1991. (Pubitemid 21924099)
40. Tsai LC, Hung MW, Yuan CC, Chao PL, Jiang SY, Chang GG and Chang TC: Effects of tamoxifen and retinoic acid on cell growth and c-myc gene expression in human breast and cervical cancer cells. Anticancer Res 17: 4557-4562, 1997. (Pubitemid 28081744)